Log in

Log in

Clinical Proteome Tumor Analysis Consortium (CPTAC)

The U.S. National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research (OCCPR) aims to improve prevention, detection, diagnosis, and treatment of cancers by enhancing the understanding of the molecular mechanisms of different cancers, advancing proteome science and technology development, and accelerating the translation of molecular findings into the clinic.

OCCPR manages the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC), which is a comprehensive and coordinated effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome (proteins) and genome (DNA and RNA) analysis technologies to different cancer types.  CPTAC is composed of expertise in proteomics, genomics, cancer biology, oncology, and clinical chemistry, while creating open community resources that are widely used by the cancer community.

CPTAC’s “proteogenomics” approach (intersection/convergence of proteomics and genomics), was successful in demonstrating the scientific benefits of integrating proteomics with genomics to produce a more unified understanding of cancer biology and possibly therapeutic interventions for patients, while creating open community resources that are widely used by the global cancer community.

    CPTAC Websites and Resources links:


    Henry Rodriguez, Jean Claude Zenklusen, Lois M. Staudt, James H Doroshow, Douglas R. Lowy. (2021) The next horizon in precision oncology: Proteogenomics to inform cancer diagnosis and treatment; Cell 

    Zhang, H, Liu T, Zhang Z, Payne S. et al (2016) Integrated proteogenomic characterization of human high grade serous ovarian cancer. PMID 27372738; Cell.

    Mertins P, et al (2016) Proteogenomic Analysis of Human Breast Cancer Connects Genetic Alterations to Phosphorylation Networks. PMID 27251275; Nature.

    Zhang B, et al. (2014) Proteogenomic characterization of human colon and rectal cancer. PMID 25043054; Nature.

    Ellis MJ, et al (2013) Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. PMID 24124232; Cancer Discovery.

    For more information please contact office(at)

    The Human Proteome Organization is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.  |  © 2001-2022 HUPO. All rights reserved. 

    Powered by Wild Apricot Membership Software